Medicine News and Research

RSS

Mechanism that controls embryonic development could also prevent cancer

Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth.

29 Oct 2010

GSK and Amicus announce Amigal development and commercialization agreement

GlaxoSmithKline PLC (GSK) and Amicus Therapeutics today announced a definitive agreement to develop and commercialize Amigal™ (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease, a rare inherited disorder. Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl.

29 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

Good report cards mean more money for nursing homes

Nursing homes that improve their quality of care - and thereby score high on public report cards - might see financial gains.

29 Oct 2010

Diabetic Hypoglycemia supports World Diabetes Day

Diabetic Hypoglycemia supports World Diabetes Day on the 14th November 2010 in raising the global awareness of diabetes ( http://www.worlddiabetesday.org/).

29 Oct 2010

University of Montreal contributes to '1000 Genomes Project'

Mutations in DNA are a normal part of life. Sometimes these variations give rise to unique and beneficial traits including the creation of a new species, other times they cause devastating diseases. We are now another step closer to capturing most of the DNA mutations in humans thanks to an international study cataloging all forms of DNA variation from five populations from Europe, East Asia, South Asia, West Africa and the Americas, in the "1000 Genomes Project".

29 Oct 2010

57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study

A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer.

29 Oct 2010

University of Maryland to establish major research enterprise for autoimmune diseases

With a new $45 million private gift from the family of a grateful patient, the University of Maryland School of Medicine is planning to establish the nation's only major research enterprise devoted to the study of autoimmune and inflammatory diseases such as celiac disease, multiple sclerosis, chronic obstructive pulmonary disease, asthma and Type 1 diabetes. The gift, from Indiana couple Ken and Shelia Cafferty, is the largest private donation in the history of the University System of Maryland.

29 Oct 2010

Mary Ann Liebert launches Brain Connectivity journal

Mary Ann Liebert, Inc. announces the release of a new peer-reviewed journal in an expanding area of systems neuroscience, Brain Connectivity. This timely new journal is positioned to become the premier source of cutting-edge basic and clinical neuroscience research aimed at better understanding of structural and functional connections in the brain and how these connections are altered by neurological disorders.

29 Oct 2010

Fast Neutron Radiotherapy safe and effective for treatment of non-small cell lung cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine (WSU SOM) in Detroit are presenting two research studies that found the use of Fast Neutron Radiotherapy (FNRT) – a form of radiation that is about three times more powerful than typical photon radiotherapy – is highly effective and safe for patients who are dealing with non-small cell lung cancer. The findings are being formally presented Monday, Nov. 1, at the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.

29 Oct 2010

CAN launches Highly Qualified Consumer Database about arthritis

Over 4 million Canadians suffer from arthritis, but only a tiny percentage of them are involved in influencing arthritis research in Canada. The Consumer Advisory Council (CAC) of the Canadian Arthritis Network (CAN) hopes to change that by launching a Highly Qualified Consumer (HQC) Database that will store information about Canadians willing to volunteer as consultants or collaborators to arthritis researchers.

29 Oct 2010

Memorial mass for former Loyola University Hospital cardiothoracic surgeon

A memorial Mass will be said on Friday, Nov. 12 for former Loyola University Hospital cardiothoracic surgeon Dr. Roque Pifarré, who performed the first heart transplant in Illinois.

29 Oct 2010

New biobank at Qatar helps research of major diseases

A "biobank" of samples and clinical measurements from tens of thousands of people is to be established in Qatar to help scientists understand the causes of major diseases and develop new treatments, it is announced today.

29 Oct 2010

New findings on Th17 cells pave way for human cancer treatment protocol

A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

29 Oct 2010

Access to kidney transplantation increases for elderly patients

Elderly patients with kidney failure get kidney transplants more often than they did a decade ago, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The results suggest that the chances of receiving a kidney transplant are better than ever for an older patient who needs one.

29 Oct 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Shire plc the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.

29 Oct 2010

Miami Miller School receives grant to study impact of GenerationOne's mobile solution on heart failure patients

The James and Esther King Biomedical Research Program has awarded the University of Miami Miller School of Medicine Geriatrics Institute a $100,000 grant for a year-long study on the impact of GenerationOne's Mobile Heath Solution on heart failure patients.

29 Oct 2010

Low levels of pre-treatment radiation do not risk radiotherapy efficacy in prostate, lung cancer patients

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests low levels of pre-treatment radiation mimicking the doses delivered by CT scans for image guidance pose no risk to the efficacy of radiotherapy in patients with prostate carcinoma and non-small cell lung carcinoma. The findings will be formally announced on Sunday, Oct. 31, during the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.

29 Oct 2010

Hospital group and physicians looking at ACOs; Harvard to open primary care education center

In an Oct. 27 letter to the CMS, the Federal Trade Commission and HHS inspector general's office, the Federation of American Hospitals offered comments on accountable care organizations.

29 Oct 2010

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

29 Oct 2010

Medicine News and Research

Mechanism that controls embryonic development could also prevent cancer

GSK and Amicus announce Amigal development and commercialization agreement

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Good report cards mean more money for nursing homes

Diabetic Hypoglycemia supports World Diabetes Day

University of Montreal contributes to '1000 Genomes Project'

57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study

University of Maryland to establish major research enterprise for autoimmune diseases

Mary Ann Liebert launches Brain Connectivity journal

Fast Neutron Radiotherapy safe and effective for treatment of non-small cell lung cancer: Study

CAN launches Highly Qualified Consumer Database about arthritis

Memorial mass for former Loyola University Hospital cardiothoracic surgeon

New biobank at Qatar helps research of major diseases

New findings on Th17 cells pave way for human cancer treatment protocol

Access to kidney transplantation increases for elderly patients

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Miami Miller School receives grant to study impact of GenerationOne's mobile solution on heart failure patients

Low levels of pre-treatment radiation do not risk radiotherapy efficacy in prostate, lung cancer patients

Hospital group and physicians looking at ACOs; Harvard to open primary care education center

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News